Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Auransa Inc.

www.auransa.com

Latest From Auransa Inc.

Asia Deal Watch: Boost For Esperion's Cholesterol Candidate As Daiichi Brought On Board

Daiichi Sankyo pays $150m upfront to commercialize Esperion's cholesterol drug and combination in Europe, while Gilead enters major deal worth up to $785m with Korea's Yuhan to bolster its NASH portfolio. Samsung taps 3SBio to build its biosimilars business in China. 
Deals Asia Pacific
See All

Company Information

  • Industry
  • Biotechnology
  • Digital Health
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Infectious & Viral Diseases
  • Inflammation
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Auransa Inc.
  • Senior Management
  • Pek Lum, PhD, CEO
    Viwat Visuthikraisee , PhD, COO
    Andy Protter, PhD, CSO
    Andrew Wong, SVP, Corp. Bus. Dev.
  • Contact Info
  • Auransa Inc.
    550 Hamilton Ave.
    Ste. 230
    Palo Alto, CA 94301
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register